	US 12,304,931 B2
	MENTSH analogs as therapeutics for diabetes, obesity, and their associated diseases and complications
Pinchas Cohen, Los Angeles, CA (US); and Kelvin Yen, Los Angeles, CA (US)
Assigned to University of Southern California, Los Angeles, CA (US)
Filed by University of Southern California, Los Angeles, CA (US)
Filed on Aug. 1, 2023, as Appl. No. 18/363,178.
Application 18/363,178 is a continuation of application No. 17/394,282, filed on Aug. 4, 2021, granted, now 11,760,783.
Application 17/394,282 is a continuation of application No. 16/311,599, granted, now 11,124,551, issued on Sep. 21, 2021, previously published as PCT/US2017/039139, filed on Jun. 23, 2017.
Claims priority of provisional application 62/354,573, filed on Jun. 24, 2016.
Prior Publication US 2024/0018199 A1, Jan. 18, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01); C07K 7/08 (2006.01); C07K 14/435 (2006.01); C07K 14/47 (2006.01); G01N 33/68 (2006.01)

CPC C07K 14/47 (2013.01) [A61K 38/00 (2013.01); A61P 3/04 (2018.01); A61P 3/10 (2018.01); C07K 7/08 (2013.01); C07K 14/435 (2013.01); G01N 33/6893 (2013.01); G01N 2800/04 (2013.01); G01N 2800/042 (2013.01); G01N 2800/044 (2013.01); G01N 2800/347 (2013.01)]

10 Claims

1. A composition comprising:

a peptide comprising the amino acid sequence with 70% or more percent identity to SEQ ID NO:97,

wherein the peptide comprises the amino acid sequence of any one of SEQ ID NOs: 1-20, 25-36, 43-47, 49-63, 65-87, 89, 91-93, and 95, or

wherein the peptide is 16, 17, 19, 20, 21, or 22 amino acids in length.